Veracyte Stock (NASDAQ:VCYT)

Veracyte, Inc. operates as a global diagnostics company, specializing in the development and commercialization of advanced genomic tests. The company's product portfolio encompasses several key diagnostic solutions: The Afirma Genomic Sequencing Classifier and Xpression Atlas, which help patients with indeterminate thyroid nodule results avoid unnecessary surgical procedures by identifying benign cases. Decipher Prostate Biopsy and Radical Prostatectomy tests for the diagnosis of prostate cancer. The Prosigna Breast Cancer Assay, used for breast cancer diagnosis. Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test, both designed for lung cancer diagnosis. The Envisia Genomic Classifier, which aids in diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. The Immunoscore Colon Cancer test for colon cancer detection. Veracyte is also actively engaged in developing future diagnostic tools, such as the Percepta Genomic Atlas to inform lung cancer treatment decisions; an Envisia Classifier that leverages the nCounter analysis system; and the LymphMark test for precise lymphoma subtyping. The company maintains strategic technology licensing and collaborative agreements with entities including Johnson & Johnson, Acerta Pharma, and CareDx. Incorporated in 2006, the organization was initially known as Calderome, Inc., before officially changing its name to Veracyte, Inc. in March 2008. Its corporate headquarters are situated in South San Francisco, California.